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controversial. Moreover, most of the documents on this topic were produced, by both the human reproduction societies and the endocrinology societies, with pregnancy as an immediate objective. However, reproductive abnormalities are frequently a central problem in these women beyond this specific aim, and come before and after this goal. Physicians are thus called to manage the reproductive alterations of PCOS women also when a pregnancy is not on the program, while taking into account comprehensively the whole spectrum of clinical problems of these patients. This concept is especially important for endocrinologists, who need to manage the many problems of these women for long periods, ideally for all of their lives.
With the objective of reviewing the literature on the treatment of the reproductive alterations of PCOS, and developing evidence-based guidelines aimed at improving the management of these abnormalities, The Italian Society of Endocrinology (SIE) Board appointed a panel of experts, selected from researchers who published relevant articles in the field. The project and panel composition was also steered by the conviction that the clinical issues of PCOS should be managed with a network-oriented approach, primarily through strict interaction between endocrinologists and gynecologists.
Introduction
Reproductive alterations are a mainstay of the classic definition of polycystic ovary syndrome (PCOS), as defined in 1992 by the NIH consensus statement on PCOS [1] . These abnormalities still represent one of the three cardinal aspects used for diagnosing PCOS according to the current criteria, as defined by the Rotterdam ESHRE/ASRM consensus workshop [2] and by the AE-PCOS Society [3] . In addition, the reproductive alterations of PCOS are a key point in the treatment of this condition.
Although there are several guidelines on the management of infertility in PCOS women, this issue remains 1 3 additional relevant papers. Searches were limited to articles in English. Over 1000 articles were initially available for review. Most studies were excluded because data were not related to the objective of the guideline or were not adequate for analysis. A few studies were eliminated because data had been previously reported in other publications.
Process
The Panel members constituted the Writing Committee. Each review included in the document was carried out by at least two members of the Panel, who appraised the methodological quality of the studies that met inclusion criteria, and discussed the evidence to find consensus. Thereafter, the whole Panel reviewed and approved each part of the document before submitting it to the SIE Board for final approval.
The document applied the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group criteria [4, 5] . According to such criteria, the Panel used 'recommend' for strong recommendations, and 'suggest' for weaker recommendations.
In this regard, the panel made an effort to use the best available research evidence to develop the recommendations. Studies were classified according to the levels of evidence and evaluated with a priori criteria based upon the study design, using a descriptive approach to assign a risk of bias rating. In the selection of papers, special consideration was given to the presence of well-performed RCTs, where available. Several aspects of the studies, such as criteria for selection of patients, methods of randomization, blinding, sample size, duration of studies and methodology used for assessment of the endpoints were assessed. In the absence of adequate evidence-based data, conclusions were derived from lower quality evidence, or even from the unsystematic observations of the panelists and their opinions, based on available data and clinician judgement. Nevertheless, these aspects were carefully considered by the whole panel when grading the strength of the recommendations. Importance of the outcome, risks and burdens of therapy, and resource costs were also considered in establishing the strength of recommendations.
Diagnosis of infertility/oligoanovulation

Adolescent girls
In the perimenarcheal phase, many adolescent girls exhibit a state of anovulation. More than 80 % of cycles are anovulatory during the first year, 60 % during the third and 25 % even in the sixth year after menarche [6] . Therefore, making a diagnosis of ovarian dysfunction in adolescents is challenging. Nevertheless, anovulatory otherwise normal menstruating girls often show elevated LH levels and androgen imbalance [7] , suggesting susceptibility to developing PCOS later in life.
Currently, no unambiguous criteria to diagnose PCOS during adolescence exist. Careful follow-up is recommended to evaluate persistent oligoamenorrhea as a potential early sign of PCOS, especially when it persists over 2 years beyond menarche and/or is associated with hyperandrogenism [8, 9] .
Adult women
Chronic anovulation In adult women, chronic anovulation is one of the cardinal criteria used in diagnosing PCOS. Since up to 25 % anovulatory women with hyperandrogenic symptoms may have substantially regular menses, ovulatory function should be systematically investigated in these subjects [3] . By contrast, chronic anovulation may be assumed in adult women with oligoamenorrhea, although ovulation may occasionally occur, especially in those women who have less severe menstrual dysfunction.
Ovulation can be detected by measuring serum progesterone in the luteal phase, about 1 week before the expected day of the next menstruation. In women with mild menstrual dysfunction, serial weekly measurements of serum progesterone for 2-3 weeks can be considered. Hormone levels suggesting ovulation are ≥5-8 ng/mL. As occasionally anovulation may occur in healthy women and ovulation in PCOS women, ovulatory function should be assessed in at least two different cycles. Notably, long-term oral contraceptive (OC) use may mask or delay recognition of menstrual dysfunction or hyperandrogenic symptoms.
Blood testing and pelvic ultrasounds should not be performed in these women until they have discontinued OC for at least 3 months. When appropriate, pregnancy should be excluded by specific testing. Moreover, other causes of reproductive dysfunction, such as weight-and exerciserelated causes, hyperprolactinemia, thyroid dysfunction, adrenal dysfunction and premature ovarian failure should be ruled out.
Infertility Diagnosis of PCOS does not exclude other abnormalities. Male factors, tubal patency, endometriosis and other more rare causes must be considered, and patients referred to reproduction specialists. Finally, the infertility workout in PCOS patients should always consider the presence of obesity and other metabolic alterations.
Mechanisms of infertility in PCOS women
Overall, PCOS accounts for most ovulatory disorders, and oligoanovulation is the most common cause of infertility in these women. Nevertheless, other factors, including reduced oocyte competence and endometrial receptivity may be involved [9] . In accordance with these observations, a reduced conception rate, relative to the ovulation rate, and an increased rate of early pregnancy loss may contribute to infertility in these women. Obesity, which is a common finding in PCOS women, has an additional adverse impact on reproduction [10] .
The mechanisms responsible for reproductive alterations may include androgen overproduction, gonadotropin abnormalities, antimullerian hormone (AMH), insulin and insulin resistance, and other factors.
Androgen excess
Women with PCOS are characterized by increased theca cell androgen production. The hyperandrogenic milieu has critical adverse effects on follicle growth and recruitment and on granulosa cell function, thereby disrupting reproductive processes. Studies in experimental animals showed that an increased androgen milieu may induce the ovarian morphological alterations typical of PCOS, with theca cell hypertrophy and excess numbers of early stage ovarian follicles, leading to a vicious circle [11] . In anovulatory women with PCOS, antral follicle growth stops when their diameter is less than 10 mm, precluding dominant follicle emergence. It was hypothesized that the increased number of immature follicles may depend on a trophic effect of androgens on follicular cells. In accordance with this hypothesis, testosterone may both stimulate follicular growth, by increasing FSH receptor expression in granulosa cells, and prevent follicular atresia, by inducing the antiapoptotic microRNA-125b [12] . Nonetheless, disordered early folliculogenesis may also be the consequence of genetic alterations involving the initial process of follicle growth.
Gonadotropin abnormalities
Approximately two-thirds of PCOS women have accelerated GnRH and LH pulse frequency, with increased serum LH. This alteration is more frequent in normal-weight patients. However, high concentrations of androgens may desensitize the hypothalamus to negative feedback by progesterone [13] , suggesting that gonadotropin abnormalities in PCOS may be a secondary phenomenon, due to the abnormal steroid environment.
AMH
Physiologically, AMH seems to act as a follicular gatekeeper, limiting initiation of follicle growth and estrogen production. AMH is expressed in granulosa cells of small growing follicles, and available data support that it is involved in the regulation of small follicle growth and threshold for FSH sensitivity. Women with PCOS have markedly increased blood AMH levels, likely due to both an increased number of small antral follicles and intrinsic characteristics of granulosa cells [14] . These data support the concept that increased AMH might contribute to anovulation and infertility in PCOS women. Alternatively, it might imply increased oocyte pool size, with a potential increase in the reproductive lifespan. In this regard, many authors believe that AMH increased levels may be a mirror of disordered early folliculogenesis, and do not participate in dominant follicle selection and growth.
Insulin and insulin resistance
Insulin resistance with associated hyperinsulinemia is a frequent finding in women with PCOS, especially in those with obesity and visceral fat expansion [15] . Human studies have demonstrated that insulin can increase circulating androgens in women with PCOS, while reducing SHBG levels. Interestingly, insulin suppression by pharmacological intervention can decrease serum androgens in women with PCOS, but not in healthy women, suggesting that PCOS-specific abnormalities may be a prerequisite for the reproductive effects of insulin [15] . In vivo studies showed that sustained hyperinsulinemia may potentiate both gonadotropin-stimulated ovarian androgen steroidogenesis [16] and ACTH-stimulated adrenal androgen steroidogenesis [17] , possibly through overactivation of the cytochrome P450 17alpha-hydroxylase/17,20-lyase (CYP17) pathway [18] . Hyperinsulinemia might contribute to anovulation also reducing pituitary sensitivity to GnRH [19] .
Other factors
Adiponectin blood levels are reduced in PCOS women. In particular, plasma high-molecular weight adiponectin, which is most closely related to insulin sensitivity, was found to be reduced in these patients, especially in those in the highest quartiles for WHR and free testosterone [20] . Evidence is growing that adiponectin receptors are expressed in theca cells and that adiponectin may modulate ovarian steroidogenesis [21] , suggesting that defective adiponectin action may contribute to androgen excess in PCOS, linking metabolic and reproductive dysfunction in these women.
Interestingly, in vitro studies have demonstrated that pro-inflammatory stimuli may upregulate theca cell enzymes responsible for androgen synthesis. These findings support the hypothesis that low-grade chronic inflammation, a characteristic of many PCOS women, may stimulate the polycystic ovary to produce androgens, disrupting ovulatory function [22] .
Several recent data suggest that also advanced glycation end products (AGEs), which are produced in the body by chemical reactions and introduced with diet, may have a role. They can mediate inflammatory and oxidant stimuli, causing chronic anovulation and increased androgen synthesis, both acting directly on the ovary and contributing to the impairment of insulin action [23, 24] .
Finally, it must be mentioned that accumulating data indicate that early folliculogenesis is under strict regulation by local intraovarian factors. In this regard, several oocyteand granulosa cell-derived factors may modulate preantral follicle growth, although the specific mechanisms driving the activation of primordial follicles need to be clarified [25] . It is still unclear whether these factors play a role in the pathophysiology of PCOS.
Management of infertility in PCOS women
Therapeutic tools
When an infertile PCOS woman seeks medical assistance with the specific aim of having a baby, the physician must select from the different therapeutic tools available for this condition, after a careful diagnostic assessment has excluded other causes of infertility. In the decision process several factors should be balanced, primarily efficacy, safety and costs of therapies, but also the medical history and characteristics of the patient.
For obese subjects, weight loss by lifestyle intervention is essential, to both facilitate ovulation and prevent obesityassociated pregnancy complications [9] . However, the individual response to weight loss is variable [26] and there are very limited data on the efficacy of this approach in terms of pregnancy and live birth rates [27] . Some uncontrolled trials suggested that weight loss may increase pregnancy rates and reduce need for specific fertility therapies [28, 29] , but there is a lack of RCTs of adequate quality. In the clinical experience most obese women require further intervention, whereas there is no evidence that lifestyle changes may be effective in normal-weight patients. Nevertheless, the hypothesis that dietary modifications could be potentially relevant in these women independently of calorie intake and body weight loss cannot be ruled out [23, 24] .
In the past, customary management of infertility in PCOS women was surgical, by ovarian wedge resection. Transient resumption of ovulation following reduction of androgen-secreting ovarian mass is a likely explanation for the efficacy of this procedure. However, this technique was abandoned in the early 1980s, because of the risk of secondary sterility due to the development of periovarian adhesions, and the availability of pharmacological therapy to induce ovulation. More recently, a new, less invasive, surgical approach, laparoscopic ovarian drilling (LOD), has been introduced, although there are still concerns about the long-term consequences on ovarian function. A recent metaanalysis of RCTs comparing this technique vs other treatments of infertility, in clomiphene-resistant PCOS women, reported that both clinical pregnancy and live birth rates were similar in subjects assigned to LOD or other medical therapies, although live birth rate was lower following LOD than combined therapy with clomiphene plus metformin [30] . Conversely, the multiple pregnancies rate was lower in LOD-treated women than in those undergoing therapy with gonadotropins [30] .
However, the preferred current approach to infertility in PCOS women is by pharmacological induction of ovulation [9, 31, 32] . In this regard, there are several potentially available tools, including medications lowering estrogen action or blood levels-which stimulate ovulation by provoking an increase in endogenous gonadotropins-exogenous gonadotropins, and insulin sensitizers.
The most common pharmacological therapy for anovulation in PCOS women is by the selective estrogen receptor modulator clomiphene, although resistance to this medication (defined as failure to ovulate after taking the 150 mg per day dose of the drug) occurs in approximately 15-40 % of women [33] . Notably, higher rates of resistance have been reported in obese patients. Hyperandrogenemia, age and severity of menstrual abnormalities are other factors predicting a less favorable outcome of clomiphene treatment [31] . Ovarian volume was reported as an additional predictor of ovulatory response to this drug. However, data are controversial and there are no specific exclusion criteria for using clomiphene in women with anovulatory infertility [31] .
Clomiphene has been used as the reference therapy in most RCTs comparing different strategies aimed at improving ovulation in these patients. In many, although not all, trials comparing clomiphene and metformin, clomiphene performance was better in terms of pregnancy and live birth rates [34] , whereas metformin showed possible advantages in terms of reduced risk of multiple pregnancies. Conversely, comparison of clomiphene vs injectable gonadotropins showed similar reproductive performances in terms of live birth rate at the intention-to-treat analysis, although low-dose FSH was slightly better in the per protocol analysis [35] . These findings should be balanced against the marked differences in terms of cost effectiveness, favoring clomiphene.
Only limited data are available on the comparison between clomiphene and aromatase inhibitors. Interestingly, a recent large multicenter RCT has shown that the aromatase inhibitor letrozole may be more effective than clomiphene, in clomiphene-naïve PCOS women, in terms of live birth rate [36] . However, although this study did not show statistically significant differences in terms of safety parameters, experience with aromatase inhibitors in pregnant women is very limited and there are still some concerns about their potential teratogenicity. In this regard, in the above-mentioned study there were four major congenital anomalies in the letrozole group versus one in the clomiphene group. This difference was not statistically significant, but the study has not been powered to detect differences from this point of view.
The role of insulin sensitizers in the treatment of PCOS women is also controversial. A recent metaanalysis concluded that metformin is of limited utility in improving the reproductive outcomes of PCOS women, despite the improved ovulation and clinical pregnancy rates, due to the lower live birth rate observed with this drug as compared to clomiphene [34] . Nevertheless, metformin may have some interest in infertile women with PCOS as an adjuvant agent. In this regard, another metaanalysis concluded that the combination metformin plus clomiphene was better than clomiphene alone in terms of live birth rate, in clomiphene-resistant PCOS women (RR 6.4, 95 % CI 1.2-35) [37] . In the metaanalysis metformin was also better than LOD in terms of live birth rates. The recently published guidelines of the Society of Obstetricians and Gynecologists of Canada [38] suggested that metformin may be added to clomiphene for ovulation induction, especially in PCOS subjects who are older and have evidence of visceral obesity. This conclusion was primarily based on the findings of an RCT showing an advantage with combined therapy in women 28 years or older and with a waist-to-hip ratio over 0.85 [39] . There is a lack of RCTs with other insulin sensitizers.
Finally, in vitro fertilization (IVF) may also be used for management of these women. In a recent retrospective cohort study, live birth rate after IVF was similar in PCOS women and age-matched controls, although rates of miscarriage and moderate to severe ovarian hyperstimulation syndrome (OHSS) were higher in PCOS subjects [40] .
Notably, metformin may reduce the risk of OHSS in PCOS women receiving gonadotropin therapy, whereas it showed no effect on the numbers of oocytes collected during IVF [41] .
Therapeutic strategy
The medical approach to infertility in PCOS women should be personalized. Lifestyle intervention with low-calorie diet and regular exercise is always recommended in overweight/ obese subjects, to obtain adequate weight loss before any specific treatment.
Clomiphene citrate should still be considered the firstline medical therapy to induce ovulation in these women, in addition to lifestyle measures when appropriate.
Clomiphene doses can vary from 50 mg up to 150-200 mg a day for 5 days, usually starting on the third to the seventh day after spontaneous or induced menstruation. When ineffective, this treatment should be maintained for at least 4-6 months before moving on to other therapies.
Metformin is not recommended as a primary treatment for infertility in PCOS women, although this drug showed favorable effects on ovulation and pregnancy rate in these patients [37] . However, the addition of metformin to clomiphene may improve pregnancy rates in clomiphene-resistant women, especially those with moderate visceral obesity [39] , and combined therapy may be considered a second-line approach. Metformin doses used in PCOS women generally vary from 1000 to 2500 mg per day, although adequate dose finding trials are lacking. To avoid or limit the gastrointestinal side effects of metformin, it is advisable to start with low amounts, i.e., 500 mg per day, and increase the dose gradually, by 500 mg weekly, up to the prefixed or the maximum tolerated posology. Use of this medication remains off-label in nondiabetic subjects.
Gonadotropin therapy is recommended as a third-line approach for infertility in PCOS women, whereas LOD may be used in selected cases managed by centers with specific skills. Nevertheless, conventional gonadotropin therapy may be challenging in these women, due to risks of multiple follicle development, multiple pregnancies and/or OHSS [42] . Therefore, very careful monitoring is required during stimulation. The recommended strategy is to slowly increase FSH dose, generally with a low starting dose of 25 IU weekly, followed by an increase of 25 IU until follicles are greater than 12 mm. Higher cancelation rates were reported with 50 IU FSH increments [43] . No significant differences on ovulation induction and pregnancy rates have been found between protocols using recombinant FSH or urinary FSH, as well as between those using FSH only and FSH followed by low-dose hCG [44] . However, available data are still limited. Clinical trials also showed similar outcomes in protocols including or not including GnRH-agonists or antagonists administration [45] . Metformin does not improve the ovulation rates in PCOS patients who receive gonadotropins. However, combined therapy may favor mono-ovulatory cycles and reduce OHSS risk [46] . Finally, in infertile PCOS patients who are not responsive to other therapies, IVF is recommended as a fourthline strategy.
Notably, in those patients who seek pregnancy and suffer from significant hirsutism, treatment of excessive hair growth can rely only upon cosmetic procedures, as any pharmacological approach to hirsutism is contraindicated in pregnant women, and must be delayed until after delivery [47] .
Management of reproductive dysfunction in women not seeking pregnancy
Very few studies have been dedicated to the management of reproductive alterations of PCOS when pregnancy is not an immediate objective. Treatment must meet several needs of these individuals, including the psychological implications of irregular/absent menstruation, the request for contraception, the risks linked to unwanted pregnancies, and the risk of endometrial hyperplasia.
Obesity is associated with reproductive dysfunction and exacerbates several aspects of the clinical picture of PCOS. Therefore, lifestyle intervention is unanimously considered the first-line therapeutic strategy in obese/overweight individuals. Nevertheless, most evidence of lifestyle general benefits derives from studies carried out in people with other disorders characterized by insulin resistance, whereas studies evaluating the benefits on anovulation and menstrual dysfunction are very scarce and constrained by small sample size and short observation [27] , precluding a reliable estimation of the reproductive efficacy of this strategy. In obese PCOS women, a single small report suggests that menstrual alterations may be improved by reducing body weight by at least 5 % [48] . However, response to weight loss is variable and not all patients normalize menses and ovulatory function [26] . Interestingly, recent data suggest that in these women the improvement of ovulatory function may be mostly associated with the loss of intra-abdominal rather than total or subcutaneous fat [49] .
In most cases OC may be used for controlling all reproductive issues of PCOS women not seeking pregnancy, although there remain some concerns, especially in obese and older patients. Insulin sensitizers may also be considered for these subjects. In particular metformin can resume both regular menstruation and ovulation, while improving the metabolic alterations [50] . Although other therapies have been suggested, there is still paucity of data on these alternative tools.
Estroprogestins
In PCOS women not seeking pregnancy, OC usually represents the first-choice treatment and is often used long term. Due to the lack of adequate comparative trials, it is still debated whether specific OC formulations should be preferred in these subjects. Nonetheless, in those patients who are hirsute, formulations containing a neutral (i.e., devoid of substantial androgenic activity, such as desogestrel or gestodene) or an antiandrogenic progestin (such as cyproterone acetate, CPA) appear to be a rational choice [47] . However, these patients have increased metabolic and possibly cardiovascular risk and the prolonged use of combined OC may theoretically have adverse effects on these aspects.
Unfortunately, no data on the long-term impact of estroprogestins in PCOS women are available and most literature on these subjects investigated the effects of short-term treatment in young individuals. Therefore, recommendations must be based on information available in the general population, while taking into account the limited findings obtained in these women [51] .
Data obtained in large observational studies, carried out in the general population, showed that OC use marginally increases risk of both cardiovascular events, such as myocardial infarction and thrombotic stroke, and venous thromboembolic events (VTE) in young healthy women. However, age and other cardiovascular risk factors, such as smoking and diabetes, may worsen these risks [52, 53] . PCOS women frequently show several metabolic abnormalities, with an increased prothrombotic state and a higher rate of type 2 diabetes mellitus, which suggest increased risk of cardiovascular disease [54] . Nevertheless, these alterations are not universal in people with PCOS. Notably, in the general population, risk associated with OC use may differ according to estrogen dose and progestin type [52, 53] . In particular, a slight increase in VTE risk was observed with either antiandrogenic progestins, such as cyproterone acetate and drospirenone, or third-generation progestins, such as desogestrel or gestodene, as compared with second-generation progestins, such as levonorgestrel. Nonetheless, it was estimated that about 2000 women of the general population would have to shift from the former to the latter formulations to prevent a single venous thromboembolic event in 1 year [52] . As regards risk of arterial thrombosis, the results of large observational studies are controversial. Although some previous studies suggested that third-generation OC may carry lower risk from this point of view [51] , recent studies showed small, not statistically significant differences according to the progestin type [53] . Available information on risk associated with the use of alternative routes of hormonal administration, such as vaginal ring or transdermal patch, is very limited. However, this risk seems to be relatively high [53] , possibly due to the sustained ethinyl estradiol concentrations associated with these formulations [55] .
Based on these findings, it seems important to distinguish between PCOS patients with normal body weight and no specific metabolic or cardiovascular abnormalities and patients who are obese or have specific risks. It remains unclear whether the phenotypic aspects of PCOS may be a relevant issue in prescribing OC therapy. In this regard, the "Classic" PCOS phenotype carries an increased risk of metabolic dysfunction [56, 57] . However, the potential implications of these findings in terms of estroprogestin use in PCOS individuals need further research. Finally, special problems may be related to using OC in women of a late reproductive age.
Young lean PCOS women with no specific metabolic and/ or cardiovascular abnormalities
Oral contraceptive use in these subjects may be considered generally safe. Available information, obtained in observational studies, shows no substantial changes in glucose tolerance with OC containing low-dose estrogen, combined with any progestins, although some deterioration was reported in patients treated with relatively high doses of estrogen (0.035 mg) combined with CPA (Table 1) . Furthermore, mild increases of HDL-C and triglycerides with neutral effect on LDL-C were reported with most formulations, although some increase of LDL-C was seen with CPA-containing preparations ( Table 2) .
No information is available on incidence/prevalence of type 2 diabetes in OC-treated young women with PCOS. However, because no substantial abnormalities of glucose metabolism have been found in short-term studies, risk of diabetes in these women is likely similar to that estimated in the general population of similar age, which is negligible [58] .
Observational studies suggest that VTE risk may be slightly increased in PCOS patients, as compared with the general population (OR 1.5 in a large sample of women with PCOS, at a mean age of 29 years) [59] . Risk seems to be further increased in patients taking OC, when compared with the general population using estroprogestins (OR 2.14) [59] . However, the absolute risk remains low (27 women/10,000). In addition, part of this risk may be due to the higher prevalence of obesity in women with PCOS.
There are no data on cardiovascular events linked to estroprogestin use in PCOS. Available information suggests the absolute risk is very low and should not deter the physician from using hormonal contraception in young PCOS patients without specific risk factors.
In this context, in the opinion of this panel, for young nonobese PCOS women with no significant metabolic abnormalities, it is possible to choose from various OC formulations, according to the preferences of the physician and patient, and the specific clinical characteristics of the patient. 
Young obese PCOS women
Available data suggest there may be mild deterioration of glucose tolerance with all estroprogestins, while the lipid profile may be worsened particularly by preparations containing CPA, with increased triglycerides and possibly LDL-cholesterol (Tables 3, 4 ). Nevertheless, in most subjects serum lipids remain within the normal range.
No studies have addressed whether VTE risk is increased in young obese PCOS women. However, it was reported that in the general population the Odds ratio is 1.65 for BMI 25-30, 1.84 for BMI 30-35, and 4.34 for BMI >35 kg/m 2 , respectively [60] . Moreover, risk is further increased by estroprogestins, especially those containing high-dose estrogen, CPA or third-generation progestins, including drospirenone [61] . Because of these findings, the UK Royal College of Obstetrics and Gynaecology advises that OC should be prescribed with caution in women with BMI ≥35, and not used in those with BMI ≥40 kg/m 2 [62] . Nonetheless, VTE risk should be balanced against risks linked to pregnancy in severely obese subjects. In addition, estroprogestins may reduce the risk of endometrial carcinoma. Information on cardiovascular events is lacking in these women.
PCOS women of late reproductive age
After the age of 40, incident metabolic abnormalities, such as type 2 diabetes or metabolic syndrome, progressively increase in women of the general population, with raised risk of cardiovascular and VTE events. This risk is significantly higher in OC users [52, 53] . In the same age period, prevalence of metabolic alterations appears to be strikingly higher in PCOS women [15] . We can thus speculate that older PCOS women might face a greater increase in risk of adverse events when using OC. However, information about risk associated to estroprogestin use in individuals with PCOS is virtually absent.
The proposed strategy for using OC in these individuals is summarized in Table 5 . In subjects considered at significant risk, progestin-only contraception should be considered. This approach is associated with some minor side effects, especially unpredictable vaginal bleeding during the first months of use [62] , but is without any measurable cardiovascular and VTE risk [52, 53, 63] .
Insulin sensitizers
In the last two decades, several studies have addressed the efficacy of insulin sensitizers, particularly metformin, on the reproductive issues of PCOS. The results of comparisons between these medications and standard strategies of ovulation induction in terms of pregnancy and/or live birth rates have been discussed above. Nonetheless, this analysis does not exhaust the potential role of insulin sensitizers in the management of reproductive abnormalities of PCOS.
Although regular menses may be easily obtained using estroprogestins, OC cannot always be safely prescribed, due to specific contraindications. In addition, if anovulation is viewed as a key marker of the disorder underlying PCOS, then resumption of ovulation is the best evidence of the correction of these abnormalities. Finally, while ovulation induction is necessarily a short-term strategy, insulin sensitizers can be used long term. Therefore, these medications may be included among the strategies aimed at improving the reproductive aspects of PCOS, particularly in subjects without an urgent desire for pregnancy [15, 50, [64] [65] [66] [67] [68] .
The vast majority of studies on this issue explored the effects of metformin, whereas data on thiazolidinediones and inositol are extremely limited [34] . Although the differences between studies, in terms of experimental design and endpoint assessment, make it difficult to compare the results of these trials, collectively available data support the conclusion that insulin sensitizers may be a useful tool for the long-term management of reproductive outcomes of PCOS [15, 50, [64] [65] [66] [67] [68] .
The main conclusions deriving from analysis of these data, predominantly referred to metformin, may be summarized as follows: --Likelihood of ovulation during therapy with insulin sensitizers may be about double the spontaneous occurrence without treatment; --The percentage of responders in terms of menstrual dysfunction may be estimated to be approximately 50-60 %, whereas the percentage of responders in terms of ovulation could be less, 30-40 %; --Predictors of efficacy of treatment remain uncertain, although the presence of moderate weight excess/insulin resistance could favor, and pronounced hyperandrogenism could reduce, the clinical efficacy of this strategy; --Information about the optimal dose of medication for the reproductive endpoints is very limited. The most commonly used metformin doses range between 1.5 and 2.0 g per day.
Metformin use in PCOS women is also supported by its favorable effects on insulin resistance and the associated metabolic abnormalities, which are common findings in these subjects. However, it was proposed that this medication should be used for this purpose only when there is inadequate response to lifestyle intervention. Interestingly, regarding the cardiometabolic aspects, recent data showed that metformin may be better than OC in lowering serum AGEs and markers of inflammation, even in normal-weight PCOS women [69] . When clinically appropriate, combined therapy with metformin and OC could be considered, although this approach obviously precludes physicians from appreciating any reproductive benefit of insulin sensitizers. It was recently reported that combined therapy might favorably affect body composition, as compared with OC alone [70] .
Other tools
Other approaches have been proposed to improve the reproductive outcomes of PCOS, but interest in their clinical use remains limited. Among them acupuncture may improve menstrual pattern and ovulatory function, according to results of short-term, small-size studies [71] . Effects on the sympathetic output and beta-endorphin production may account for these findings. However, further research is needed.
Some recent studies showed that statins may have favorable effects on several aspects of PCOS. However, data from RCTs evaluating the reproductive alterations of PCOS are still inconclusive [72] . Moreover, recent data suggest that statins may further deteriorate insulin sensitivity in these patients [73] . In addition, these drugs are potentially teratogenic and their use to improve ovulation does not appear to be a safe strategy. Therefore, statins cannot be recommended for treatment of ovulatory dysfunction in PCOS subjects, whereas their use for lowering serum cholesterol, when appropriate, should be combined with adequate contraception. Similarly, limited evidence suggests that pure antiandrogen flutamide may have favorable effects on ovulation in PCOS women [74] . However, risk of severe liver toxicity, which is rare, but may occur even at low doses [75, 76] , and potential embryotoxicity make this option inappropriate for the management of reproductive alterations.
Finally, bariatric surgery may be a potentially useful tool in severely obese women with PCOS. In selected cases, metabolic surgery may resolve signs and symptoms of PCOS in these women, restoring insulin sensitivity, androgen levels and fertility [77] . 
Concluding remarks
Reproductive alterations are a very common and clinically important issue in women with PCOS. We recommend applying evidence-based strategies in the management of these abnormalities, tailored according to the characteristics and needs of each individual patient.
Our recommendations are summarized in Table 6 . Lifestyle intervention may reduce metabolic risk and pregnancy complications and is always recommended in overweight/ obese PCOS patients, although its role in the treatment of reproductive issues remains uncertain.
In most infertile PCOS women, clomiphene is the firstline therapy for ovulation induction. Metformin may be combined with clomiphene in clomiphene-resistant subjects, as a second-line approach. The recommended thirdline therapy uses gonadotropins, with careful monitoring of ovarian response, and possible combination with metformin to reduce ovarian hyperstimulation risk. In vitro fertilization is recommended when all these strategies fail.
In PCOS women with reproductive alterations not seeking pregnancy, hormonal contraceptives, metformin or both may be used for the management of reproductive abnormalities. Several features, such as age, anthropometric and metabolic characteristics, need for contraception and specific contraindication should guide this choice. Informed consent Not applicable (review of available literature and development of recommendations). Table 6 Key points and summary of recommendations 1.1. PCOS is a heterogeneous condition and the reproductive issues of PCOS women require an individually tailored approach 2.1. Although evidence that weight loss may improve the reproductive alterations of PCOS patients is limited, we recommend lifestyle intervention as a first-line strategy in all overweight/obese women with PCOS, whatever the specific reproductive goal, also bearing in mind the consequences of excess fat on metabolic aspects and pregnancy complications 3.1. When infertile PCOS women seek medical assistance for programming a pregnancy, after exclusion of other causes of infertility, we recommend clomiphene as the first-line medical therapy to induce ovulation 3.2. Metformin is not recommended as a primary treatment for infertility in PCOS women. However, we suggest combining metformin with clomiphene as a second-line strategy, in clomiphene-resistant individuals 3.3. We recommend gonadotropin therapy as third-line strategy for infertility in PCOS women. Metformin may be used as an adjuvant to prevent OHSS in women undergoing gonadotropin stimulation 3.4. In those infertile PCOS patients who are not responsive to other therapies, we recommend IVF as fourth-line strategy 4.1. We suggest OC, metformin or both for the management of reproductive dysfunction in PCOS women not seeking pregnancy. The choice should be personalized, after evaluation of the characteristics and needs of each individual subject 4.2. In young lean women with PCOS, the metabolic effects of OC containing 0.030 mg or less of ethinyl estradiol are mild and should not influence the choice of the estroprogestin preparation, although it may be safe to re-assess (e.g., after 3 months of treatment) the lipid profile and the glucose tolerance in those PCOS patients given higher dose OC containing cyproterone acetate 4.3. In young PCOS patients with moderate obesity, the risk/benefit balance for OC use appears to be generally favorable. In older women, we suggest choosing products containing low-dose estrogen and second-generation progestins 4.4. In PCOS patients with severe obesity (BMI ≥40) we suggest using combined OC only in selected patients, after very careful consideration of the advantages vs risks balance. If contraception is needed, alternative measures should be preferred, such as progestin-only methods. We suggest avoiding use of combined OC in severely obese women of late reproductive age 4.5. It remains unclear whether the phenotypic aspects of PCOS may be a relevant issue in prescribing OC therapy. Although the "Classic" PCOS phenotype may carry an increased risk of metabolic dysfunction, the implications of these findings in terms of estroprogestin use in PCOS individuals need further research 5.1. We suggest metformin for those PCOS women not seeking pregnancy who wish for long-term resumption of ovulation, especially those with metabolic alterations with an inadequate response to lifestyle intervention 5.2. Combined therapy with metformin and OC might be considered in some PCOS individuals, aimed at attenuating the adverse metabolic effects of OC and improving body composition
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